However, vorinostat has been shown to increase the expression of the norepinephrine transporter, which is the target and path of entry for radiolabeled MIBG into neuroblastoma cells (More et al., 2011), and a randomized phase 2 trial of 131I-MIBG targeted radiotherapy with or without vorinostat showed objective response rates of 14 % and 32 %, respectively, in a “pick-the-winner” trial design (DuBois et al., 2021). The gene discussed is SLC6A2; the disease is neuroblastoma.